Purpose Radioiodine has been used for the treatment of benign thyroid diseases for over 70
years. However, internationally, there is no common standard for pretherapeutic dosimetry to …

Radioiodine therapy is an effective and safe treatment of hyperthyroidism due to Graves'
disease, toxic adenoma, toxic multinodular goiter. We compared the outcomes of a …

Aim The use of radioiodine therapy is common in the treatment of benign thyroid disease.
Council directive Euratom 97/43 requires that for all medical exposure of individuals for …

Radioiodine has been in use for over as a treatment for hyperthyroidism. Major changes in
clinical practice have led to accurate dosimetry capable of avoiding the risks of adverse …

Calculation of the therapeutic activity of radioiodine 131 I for individualized dosimetry in the
treatment of Graves' disease requires an accurate estimate of the thyroid absorbed radiation …

The traditional algorithms (Marinelli–Quimby and MIRD) used for the absorbed dose
calculation in radionuclide therapy generally assume that the mass of the target organs does …

Purpose: The precise determination of organ mass (mth) and total number of disintegrations
within the thyroid gland () are essential for thyroid absorbed‐dose calculations for …

The application of an individualised dosimetric procedure for radioiodine therapy requires
the intensive use of resources in nuclear medicine facilities. In practice, the amount of data …

Aim 131 I therapy is increasingly used for Graves' hyperthyroidism. Debate remains about
the best method for calculating the activity to administer, as well as about the potential …

Aim: In radioiodine therapy (RIT) of benign thyroid-disorders empirical half-lives (HL emp)
may be used to calculate therapeutic dose. In this study the effective half-life (HLf as well as …